RESEARCH PAPER

Retinal age gap as a predictive biomarker of future risk of Parkinson’s disease

Wenyi Hu1,2,3,†, Wei Wang4,†, Yueye Wang4, Yifan Chen5, Xianwen Shang2, Huan Liao6, Yu Huang1, Gabriella Bulloch2, Shiran Zhang4, Katerina Kiburg2, Xueli Zhang1, Shulin Tang1, Honghua Yu1, Xiaohong Yang1, Mingguang He1,2,3,4, Zhuoting Zhu1,2

1Department of Ophthalmology, Guangdong Academy of Medical Sciences, Guangdong Provincial People’s Hospital, Guangzhou, China
2Ophthalmology, Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia
3Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Australia
4State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
5John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
6Neural Regeneration Group, Institute of Reconstructive Neurobiology, University of Bonn, Bonn, Germany

Address correspondence to: Zhuoting Zhu. Tel: 03-99298361. Email: zhuoting_zhu@hotmail.com; Mingguang He. Tel: 03-99298361. Email: mingguang.he@unimelb.edu.au; Xiaohong Yang. Tel: 86 20 8382 7812. Email: syyangxh@scut.edu.cn and Honghua Yu. Tel: 86 20 8382 7812. Email: yuhonghua@gdph.org.cn

†These authors are equally contributed to this work.

Abstract

Introduction: retinal age derived from fundus images using deep learning has been verified as a novel biomarker of ageing. We aim to investigate the association between retinal age gap (retinal age–chronological age) and incident Parkinson’s disease (PD).

Methods: a deep learning (DL) model trained on 19,200 fundus images of 11,052 chronic disease-free participants was used to predict retinal age. Retinal age gap was generated by the trained DL model for the remaining 35,834 participants free of PD at the baseline assessment. Cox proportional hazards regression models were utilised to investigate the association between retinal age gap and incident PD. Multivariable logistic model was applied for prediction of 5-year PD risk and area under the receiver operator characteristic curves (AUC) was used to estimate the predictive value.

Results: a total of 35,834 participants (56.7 ± 8.04 years, 55.7% female) free of PD at baseline were included in the present analysis. After adjustment of confounding factors, 1-year increase in retinal age gap was associated with a 10% increase in risk of PD (hazard ratio [HR] = 1.10, 95% confidence interval [CI]: 1.01–1.20, P = 0.023). Compared with the lowest quartile of the retinal age gap, the risk of PD was significantly increased in the third and fourth quartiles (HR = 2.66, 95% CI: 1.13–6.22, P = 0.024; HR = 4.86, 95% CI: 1.59–14.8, P = 0.005, respectively). The predictive value of retinal age and established risk factors for 5-year PD risk were comparable (AUC = 0.708 and 0.717, P = 0.821).

Conclusion: retinal age gap demonstrated a potential for identifying individuals at a high risk of developing future PD.

Keywords: retinal age, Parkinson’s disease, prediction, older people

Key Points

- It remains to be answered whether ageing biomarkers could provide clues for Parkinson’s disease (PD) risk stratification.
- Retinal age generated by the deep learning algorithm using fundus images accurately predicts age.
- Retinal age gap (retinal age-chronological age) was independently associated with the incident PD.
- Retinal age demonstrated similar predictive value for 5-year PD risk compared with established risk factors.
- Retinal age gap demonstrated the potential as a novel biomarker to identify high-risk individuals for PD.
Introduction

Parkinson’s disease (PD) is the second most common neurodegenerative disease [1] affecting approximately 6.1 million people worldwide in 2016 [2]. The prevalence and incidence of PD increases exponentially with age [3], and ageing is the single most significant factor affecting the onset, progression and clinical presentations of PD. [4, 5]

Ageing can be described as a heterogenous process [6]. Compared with chronological age which merely indicates postnatal life, biological age measures health status in respect to the ageing process [6]. An accurate quantification of the biological ageing process is clinically important for risk stratification and early intervention for age-related diseases. Leukocyte telomere length [7], and epigenic clock based on DNA methylation levels [8], and brain age derived from brain imaging data [9, 10] are a few ageing biomarkers developed to describe the ageing process, however this area remains a fluid and ongoing area of research.

Due to its insidious onset and extensive loss of dopamine neurons (approximately 70–80%) prior to diagnosis [11], a few biomarkers of ageing have been proposed for the early detection of PD in hopes of inciting early interventions for preventing further PD progression. As early as 1985, Marttila et al. noted similar but quantitatively exaggerated immune abnormalities in individuals with PD compared with normal ageing [12]. These observations have led investigations into leukocyte telomere length [13–17], epigenetic age [18] and brain age [19, 20] for their associations with PD, albeit their associations remain ambiguous [13–17]. Further, whether biomarkers of ageing could reflect early changes in PD preceding diagnosis remain to be answered. Furthermore, with the high cost of microchips and invasive sampling procedures necessary to estimate the epigenetic clock, the time-consuming and costly features of neuroimaging have limited their application as feasible population-based methods for risk prediction. Therefore, development of biomarkers with the potential to detect early PD during the asymptomatic period is critical.

Recently, we developed a deep learning algorithm based on retinal images, which could accurately predict chronological age. In addition, the retinal age gap, i.e. the difference between age predicted by retinal image and chronological age, was identified as a viable ageing biomarker that could provide important prognostic information [21]. As an extension of the central nervous system, the retina offers a unique and accessible ‘window’ to visualise cerebral neurons and microvasculature [22, 23]. Dopaminergic deficiency and microvascular abnormalities in the retina have been implicated in patients with PD. [24–26] Further, visual dysfunction, such as abnormal colour vision, pupil reactivity, impaired eye movement and stereopsis, have been reported as one of the most common non-motor symptoms in the prodromal phase of PD. [27]

Taken together, the retinal age has the potential to be utilised as a single biomarker and/or alongside other clinical risk factors/biomarkers to identify people at high risk of PD. Therefore, the current study aimed to investigate the association between retinal age gap and incident PD using the large-scale population-based sample of the UK Biobank.

Methods

Study population

We analyse the data from UK Biobank, a population-based cohort of over 500,000 UK residents aged 40–69 years. All the participants were enrolled between 2006 and 2010 with detailed health-care questionnaires administered to obtain information on lifestyle, environment, medical history and demographic data at baseline. In addition, comprehensive physical and functional measurements including ophthalmic examinations were performed and biological samples of blood, urine and saliva were collected for further analysis. Health-related events were determined using data linkage to Hospital Episode Statistics (HES) and death registers. Details on the overall study protocol and the protocols for each test have been described elsewhere [28].

This study was granted approval by The National Information Governance Board for Health and Social Care and the NHS North West Multicenter Research Ethics Committee (11/NW/0382). With the UK Biobank application number 62443, all investigations were conducted in accordance with the tenets of the Declaration of Helsinki, with written informed consent obtained from all participants.

Ophthalmic measures

In the UK Biobank vision cohort [29], comprehensive ophthalmic examinations were conducted including the logarithm of the minimum angle of resolution (LogMAR) visual acuity, autorefraction and keratometry (Tomey RC5000, Tomey GmbH, Nuremberg, Germany), intraocular pressure (IOP, Ocular Response Analyzer, Reichert, New York, USA), and paired retinal fundus and optical coherence tomography imaging (OCT, Topcon 3D OCT 1000 Mk2, Topcon Corp, Tokyo, Japan) in 2010. Fundus photography for each eye obtained the 45° non-mydriatic and non-stereo fundus images both optic disc- and macular-centred. We collected 131,238 images from 66,500 participants from the UK Biobank study, among which 80,170 images from 46,970 participants passed image quality checks.

Deep learning model for age prediction

Among 80,169 images of 46,969 participants, 19,200 fundus images of 11,052 participants who reported no previous disease were used to train the DL model for age prediction. To maximise the data available, we utilised images from both eyes if available. Of the remaining 35,917 participants, 83 had a history of PD prior to the baseline examination, yielding 35,834 participants eligible for analysis to examine the association between retinal age gap and risk of PD. If available, images from the right eye were included in the
Definition of retinal age gap
We defined the difference between retinal age predicted by the DL model and chronological age as the retinal age gap. A positive retinal age gap suggests that the retina appears ‘older’ than the patient’s chronological age, while a negative retinal age gap suggests that the retina appears ‘younger’.

Parkinson’s disease ascertainment
PD was determined via hospital administration data in England, Scotland and Wales, the national death register data and self-reported data. PD was defined by self-report codes collected and the International Classification of Diseases Version 9 (ICD-9) code 332.0 and ICD-10 code G20. History of PD was defined as the presence of PD prior to the baseline examination by ICD codes recorded before the recruitment date or self-reported history of PD in the questionnaire at baseline. Incident PD was defined as the first occurrence of PD during the follow-up period, from baseline examination to the 29 February 2016, using a UK Biobank algorithm (https://biobank.ctsu.ox.ac.uk/crystal/u kb/docs/alg_outcome_pdp.pdf). It integrated sources from hospital admissions records and death registry. The earliest ICD code for PD recorded in the hospital admission record were defined as the onset date of the incident PD case and date of death was treated as a proxy of PD onset date if ICD code of PD were recorded for the first time in the death registry.

Covariates
According to previous studies [30–33] PD has been associated with various factors including age (continuous), gender (female/male), ethnicity (white/others), Townsend deprivation indices (continuous), smoking status (never/former smoker/current smoker), drinking status (never/former or current), obesity (no/yes), physical activity (meeting recommendation/not meeting recommendation), history of diabetes mellitus (no/yes), hypertension (no/yes), stroke (no/yes) and the use of psychotropic medication (no/yes). These factors were considered as potential confounding factors in our study and were adjusted for to minimise the effects of these variables.

Obesity was defined as body mass index (BMI) 30 kg/m² or over. History of diabetes was defined as a diagnosis of diabetes, the use of insulin treatment or diabetic medication, or HbA1C ≥48 mmol/mol. History of hypertension was defined as a diagnosis of hypertension, the use of antihypertensive treatment, or measured systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg. History of stroke was defined as having had a UK Biobank algorithm-defined prior stroke according to self-report and hospital admissions data. The use of psychotropic medication was defined as the use of anti-depressant, anti-migraine or anxiolytic medications.

Statistical analyses
The baseline characteristics of all participants were presented as means and standard deviations (SDs) for normally distributed variables, or numbers and percentages for categorical variables. Unpaired z-test or ANOVA, and Pearson’s χ² test or Fisher’s exact test were used to compare continuous variables and categorical variables, respectively. To examine the relationship between retinal age gap and the incidence of PD, Cox proportional hazards models were fitted. The associations of both 1-year increase in retinal age gap and the quartiles of it (i.e. retinal age gap data points ranked from the smallest to the largest into four equal parts) with future PD risk were investigated. Utilising two Cox models, we performed a multivariable analysis adjusting for age; gender and ethnicity (Model I); and additionally deprivation, smoking status, drinking status, obesity, physical activity, history of stroke, diabetes mellitus, hypertension and use of psychotropic medication (Model II). Hazards ratio (HR) and 95% confidence interval (CI) were calculated as major measurements for the association. To model the potential non-linear association between retinal age gap and incident PD, a restricted cubic spline was fitted. Retinal age gap of zero was set as the reference. Sensitivity analyses were conducted to validate the results. Sensitivity analysis was performed by adjusting for age square in addition to the co-variates included in Model II (Model III) to overcome the potential non-linear relationship. Participants with PD diagnosed within 1 year of the baseline assessment were excluded for another sensitivity analysis. Multivariable logistic regression models were applied to estimate the predictive value of retinal age, and established risk factors including age, gender and smoking status [34] for 5-year PD risk. Area under the receiver operator characteristic curves (AUC) was used to estimate the discrimination. A two-sided P-value of <0.05 was defined as statistically significant. Statistical analyses were conducted using R (version 3.3.0, R Foundation for Statistical Computing, www.R-project.org, Vienna, Austria) and Stata (version 13, StataCorp, Texas, USA).

Results
Study populations
A total of 35,834 participants were included in the analysis with a mean age of 56.7 ± 8.04 years at baseline, and 55.7% of the participants were female (Table 1). During the median follow-up period of 5.83 (5.74–5.97) years, 63 (0.18%) incident PD cases were identified. Tables 1 and 2 showed the baseline characteristics of the study population stratified by quartiles of retinal age gap and by incident PD. There were significant differences in age, gender, ethnicity, Townsend index, smoking status, drinking status, obesity,
Table 1. Baseline characteristics of the study participants and stratified by quantiles of retinal age gap

| Baseline characteristics | Total | Q1       | Q2       | Q3       | Q4       |
|-------------------------|-------|----------|----------|----------|----------|
| N                       | 35,834| 8,959    | 8,958    | 8,959    | 8,958    |
| Age, mean (SD), years   | 56.7 (8.04) | 63.1 (4.81) | 59.3 (6.43) | 54.7 (7.34) | 49.8 (6.43) |
| Gender, No. (%)         |       |          |          |          |          |
| Female                  | 19,969 (55.7) | 4,565 (51.0) | 5,000 (55.8) | 5,156 (57.6) | 5,248 (58.6) |
| Male                    | 15,865 (44.3) | 4,394 (49.0) | 3,958 (44.2) | 3,803 (42.4) | 3,710 (41.4) |
| Ethnicity, No. (%)      |       |          |          |          |          |
| White                   | 33,400 (93.2) | 8,456 (94.4) | 8,411 (93.9) | 8,297 (92.6) | 8,236 (91.9) |
| Others                  | 2,434 (6.79) | 503 (5.61) | 547 (6.11) | 662 (7.39) | 722 (8.06) |
| Townsend index, mean (SD)|   | −1.09 (2.96) | −1.45 (2.79) | −1.22 (2.88) | −0.99 (3.02) |
| Smoking status, No. (%) |       |          |          |          |          |
| Never                   | 19,735 (55.4) | 4,854 (54.5) | 4,841 (54.3) | 4,871 (54.6) | 5,169 (58.0) |
| Former smoker           | 12,642 (35.5) | 3,458 (38.8) | 3,355 (37.6) | 3,104 (34.8) | 2,725 (30.6) |
| Current smoker          | 3,277 (9.19) | 594 (6.67) | 721 (8.09) | 943 (10.6) | 1,019 (11.4) |
| Drinking status, No. (%)|       |          |          |          |          |
| Never                   | 1,582 (4.43) | 441 (4.93) | 357 (3.99) | 394 (4.41) | 390 (4.37) |
| Former/current          | 34,143 (95.6) | 8,497 (95.1) | 8,586 (96.0) | 8,535 (95.6) | 8,525 (95.6) |
| Obesity, No. (%)        |       |          |          |          |          |
| No                      | 26,528 (74.4) | 6,766 (76.0) | 6,641 (74.5) | 6,605 (74.1) | 6,516 (73.1) |
| Yes                     | 9,121 (25.6) | 2,141 (24.0) | 2,276 (25.5) | 2,309 (25.9) | 2,395 (26.9) |
| Meeting PA recommendation, No. (%)| | | | | |
| No                      | 5,289 (18.0) | 1,126 (15.6) | 1,270 (17.4) | 1,379 (18.8) | 1,514 (20.2) |
| Yes                     | 24,036 (82.0) | 6,084 (84.4) | 6,031 (82.6) | 5,950 (81.2) | 5,971 (79.8) |
| History of stroke, No. (%)|       |          |          |          |          |
| No                      | 35,222 (98.3) | 8,750 (97.7) | 8,807 (98.3) | 8,826 (98.5) | 8,839 (98.7) |
| Yes                     | 612 (1.71) | 202 (2.33) | 151 (1.69) | 133 (1.48) | 119 (1.33) |
| History of diabetes, No. (%)|       |          |          |          |          |
| No                      | 33,486 (93.5) | 8,376 (93.5) | 8,370 (93.4) | 8,407 (93.8) | 8,333 (93.0) |
| Yes                     | 2,348 (6.55) | 583 (6.51) | 588 (6.56) | 552 (6.16) | 625 (6.98) |
| History of hypertension, No. (%)| | | | | |
| No                      | 8,714 (24.3) | 1,549 (17.3) | 1,920 (21.4) | 2,373 (26.5) | 2,872 (32.1) |
| Yes                     | 27,120 (75.7) | 7,410 (82.7) | 7,038 (78.6) | 6,586 (73.5) | 6,086 (68.0) |
| Use of psychotropic medication, No. (%)| | | | | |
| No                      | 31,934 (89.1) | 8,091 (90.3) | 8,045 (89.8) | 7,930 (88.7) | 7,868 (87.8) |
| Yes                     | 3,900 (10.9) | 868 (9.69) | 913 (10.2) | 1,029 (11.5) | 1,090 (12.2) |

SD = standard deviation; PA = physical activity; Q = quartile. The first quartile (Q1) is defined as the set of data between the smallest value and the 25th retinal age gap. The second quartile (Q2) is the set of data between the 25th and median value. The third quartile (Q3) is set of data between the median value and the 75th retinal age gap. The fourth quartile (Q4) is defined as the set of data between the 75th and the maximum of the retinal age gap.

Physical activity, history of stroke, hypertension and use of psychotropic medication across the four quartiles of retinal age gap (Table 1). Participants in the non-PD group were similar to those in the PD group except for age (P < 0.001), gender (P = 0.040) and smoking status (P = 0.047) (Table 2).

Retinal age gap and Parkinson’s disease

After adjusting for multiple confounding factors each 1-year increase in retinal age gap was associated with a 10% increase in the risk of future PD (hazard ratio [HR] = 1.10, 95% confidence interval [CI]: 1.01–1.20, P = 0.023; Table 3). Meanwhile, the risk of PD in participants with retinal age gap in the third and fourth quartiles (HR = 2.66, 95% CI: 1.13–6.22, P = 0.024; HR = 4.86, 95% CI: 1.59–14.8, P = 0.005, respectively) was significantly higher than that of the lowest quartile. The risk of incident PD in the second quartile was similar to that of the lowest quartile. In the restricted cubic spline model no non-linear association were found between retinal age gap and incident PD (P non-linear = 0.322).

Sensitivity analyses

As shown in Table 3, after further adjustment of age square the association between retinal age gap and incident PD remained significant. After excluding participants diagnosed of PD within 1 year of the baseline examination similar findings were observed.

Predictive value of retinal age and established risk factors for PD risk

Figure 1 shows the receiver operator characteristic (ROC) curves of using retinal age and established risk factors including age, gender and smoking status as predictors of 5-year
Table 2. Baseline characteristics stratified by incident Parkinson disease

| Baseline characteristics | Non-PD group | PD group | \( P \) value |
|--------------------------|--------------|----------|---------------|
| N                        | 35,771       | 63       |               |
| Age, mean (SD), years    | 56.7 (8.04)  | 62.8 (5.63) | <0.001\(^a\) |
| Gender, No. (%)           |              |          |               |
| Female                   | 19,942 (55.8)| 27 (42.9)| 0.040\(^b\)  |
| Male                     | 15,829 (44.2)| 36 (57.1)|              |
| Ethnicity, No. (%)       |              |          |               |
| White                    | 33,343 (93.2)| 57 (90.5)| 0.388\(^b\)  |
| Others                   | 2,428 (6.79)| 6 (9.52)|              |
| Townsend index, mean (SD)| -1.09 (2.96) | -1.65 (2.77) | 0.134\(^c\) |
| Smoking status, No. (%)  |              |          |               |
| Never                    | 19,701 (55.4)| 34 (54.0) | 0.047\(^c\)  |
| Former smoker            | 12,614 (35.4)| 28 (44.4)|              |
| Current smoker           | 3,276 (9.2) | 1 (1.59)|              |
| Drinking status, No. (%) |              |          |               |
| Never                    | 1,578 (4.42) | 4 (6.35) | 0.362\(^c\)  |
| Former/current           | 34,084 (95.6)| 59 (93.7)|              |
| Obesity, No. (%)         |              |          |               |
| No                       | 26,483 (74.4)| 45 (71.4)| 0.587\(^b\)  |
| Yes                      | 9,103 (25.6) | 18 (28.6)|              |
| Meeting PA recommendation, No. (%) |              |          |               |
| No                       | 5,279 (18.0) | 10 (20.0)| 0.718\(^b\)  |
| Yes                      | 23,996 (82.0)| 40 (80.0)|              |
| History of stroke, No. (%)|              |          |               |
| No                       | 35,160 (98.3)| 62 (98.4)| 1.000\(^c\)  |
| Yes                      | 611 (1.7) | 1 (1.59)|              |
| History of diabetes, No. (%)|              |          |               |
| No                       | 33,427 (93.4)| 59 (93.7)| 1.000\(^c\)  |
| Yes                      | 2,344 (6.55) | 4 (6.35)|              |
| History of hypertension, No. (%) |              |          |               |
| No                       | 8,701 (24.3)| 13 (20.6)| 0.495\(^b\)  |
| Yes                      | 27,070 (75.7)| 50 (79.4)|              |
| Use of psychotropic medication, No. (%) |              |          |               |
| No                       | 31,881 (89.1)| 53 (84.1)| 0.203\(^b\)  |
| Yes                      | 3,890 (10.9) | 10 (15.9)|              |

SD = standard deviation; PA = physical activity; PD = Parkinson disease; HR = hazard ratio; CI = confidence interval. \(^a\)Student’s \( t \)-test. \(^b\)Chi-squared test. \(^c\)Fisher’s exact test.

PD risk. The predictive value of the retinal-age-based model (AUC = 0.708, 95% CI: 0.638–0.778) and the risk-factor-based model (AUC = 0.717, 95% CI: 0.633–0.802) was similar \( (P = 0.821) \).

Discussion

The present study found each 1-year increase in retinal age gap was independently associated with a 10% increase in the risk of incident PD. Compared with the lowest quartile, participants in the third and fourth quartiles of retinal age gap had a 2.66- and 4.86-fold increased risk of developing PD, respectively. Further, the predictive value of retinal age and the well-established risk factors for PD were comparable in our analysis. Our findings suggest the retinal age gap has the potential to be utilised as a standalone biomarker, or conjunctively alongside other clinical risk factors/biomarkers for risk stratification to assist in clinical decision making.

To estimate a summary marker of individual neurodegeneration and microvascular ageing we employed the retinal age...
Table 3. Association between retinal age gap with incident of PD

| Retinal age gap                        | Model I       | Model II      | Model III      |
|----------------------------------------|---------------|---------------|---------------|
|                                         | HR (95% CI)   | P value       | HR (95% CI)   | P value       | HR (95% CI)   | P value       |
| All participants                        |               |               |               |
| Retinal age gap, per one age (years)   | −1.31 (4.82)  | 0.090         | 1.10 (1.01–1.20) | 0.023         | 1.11 (1.01–1.21) | 0.023         |
|                                         | (0.99–1.13)   |               | (0.86–1.50)   |               | (0.83–1.50)   |               |
| Quartile 1                              | −7.36 (3.44)  | 0.085         | 1.09 (1.00–1.19) | 0.046         | 1.09 (1.00–1.19) | 0.048         |
|                                         | (−2.62 (0.86) |               | (−0.98–1.12)  |               | (−0.98–1.12)  |               |
| Quartile 2                              | −2.62 (0.86)  | 0.074         | 1.09 (1.00–1.19) | 0.046         | 1.09 (1.00–1.19) | 0.048         |
|                                         | (−0.44–1.75)  |               | (−0.98–1.12)  |               | (−0.98–1.12)  |               |
| Quartile 3                              | 0.26 (0.86)   | 0.120         | 1.09 (1.00–1.19) | 0.046         | 1.09 (1.00–1.19) | 0.048         |
|                                         | (−0.83–3.65)  |               | (−0.98–1.12)  |               | (−0.98–1.12)  |               |
| Quartile 4                              | 4.48 (2.35)   | 0.008         | 1.09 (1.00–1.19) | 0.046         | 1.09 (1.00–1.19) | 0.048         |
|                                         | (1.40–8.91)   |               | (1.00–1.19)   |               | (1.00–1.19)   |               |

Excluding incident PD within 1 year

| Retinal age gap, per one age (years)   | Model I       | Model II      | Model III      |
|----------------------------------------|---------------|---------------|---------------|
|                                         | HR (95% CI)   | P value       | HR (95% CI)   | P value       | HR (95% CI)   | P value       |
|                                         |               |               |               |
| Quartile 1                              | −7.36 (3.44)  | 0.085         | 1.09 (1.00–1.19) | 0.046         | 1.09 (1.00–1.19) | 0.048         |
|                                         | (−2.62 (0.86) |               | (−0.98–1.12)  |               | (−0.98–1.12)  |               |
| Quartile 2                              | −2.62 (0.86)  | 0.074         | 1.09 (1.00–1.19) | 0.046         | 1.09 (1.00–1.19) | 0.048         |
|                                         | (−0.44–1.75)  |               | (−0.98–1.12)  |               | (−0.98–1.12)  |               |
| Quartile 3                              | 0.26 (0.86)   | 0.120         | 1.09 (1.00–1.19) | 0.046         | 1.09 (1.00–1.19) | 0.048         |
|                                         | (−0.83–3.65)  |               | (−0.98–1.12)  |               | (−0.98–1.12)  |               |
| Quartile 4                              | 4.48 (2.35)   | 0.008         | 1.09 (1.00–1.19) | 0.046         | 1.09 (1.00–1.19) | 0.048         |
|                                         | (1.33–9.00)   |               | (1.00–1.19)   |               | (1.00–1.19)   |               |

PD = Parkinson diseases; HR = hazard ratio; CI = confidence interval. The first quartile (Q1) is defined as the set of data between the smallest value and the 25th retinal age gap. The second quartile (Q2) is the set of data between the 25th and median value. The third quartile (Q3) is set of data between the median value and the 75th retinal age gap. The fourth quartile (Q4) is defined as the set of data between the 75th and the maximum of the retinal age gap. ‘Model I adjusted for age, gender and ethnicity. ‘Model II adjusted for age, gender, ethnicity, deprivation, smoking status, drinking status, obesity, physical activity, history of stroke, diabetes mellitus, hypertension and use of psychotropic medication. ‘Model III adjusted for age, age square, gender, ethnicity, deprivation, smoking status, drinking status, obesity, physical activity, history of stroke, diabetes mellitus, hypertension and use of psychotropic medication. Significant associations (P<0.05) are bolded.

Our findings shed light on the potential for retinal age gap to be utilised as a novel biomarker for identifying individuals at a high risk of developing PD. Retinal age gap which can be predicted through fundus photography lends itself as a potential large-scale screening tool, which could be further empowered by incorporation of smartphone-based teleophthalmology assessment [49]. Considering PD is just one of many factors potentially influencing the retinal age gap, the observed association between the retinal age gap and underlying the association remain to be elucidated, several plausible explanations can be proposed. Firstly, accelerated neurodegeneration observed in the retina might reflect the similar process in PD. Both animal [47] and population-based studies [38, 39] have provided evidence that the retina mirrors the ageing brain. When compared with subjects without PD, PD patients showed more prominent neuronal changes in the retina independent of age and other risk factors, such as increased reduction of retinal nerve fibre layer thickness [40–42]. In addition, retinal vascular alterations have been observed in PD, including decreased vessel density, perfusion density and capillary complexity [43–47]. These findings could be explained by the homogeneity of the retinal and cerebral circulation [23], and consequences of vascular ageing including mitochondrial oxidative stress on both retinal and brain vasculature [48].
the incident PD could be biased by such factors. Our analysis attempted to overcome these potential biases by adjusting for a wide array of confounding factors in the final model. A persistent significant association suggests that retinal age gap is a true biomarker for PD, independent from other known factors.

The specificity of the retinal age gap for early detection of PD is an important factor for its future application. Our findings, specifically that the increased retinal age gap was significantly associated with the greater risk of PD, has been interpreted as a byproduct of accelerating neurodegeneration and cerebral vascular ageing, however we suspect distinct patterns could be observed for other neurodegenerative diseases, such as Alzheimer’s disease [50]. Thus, the concept of retinal age gap offers a unique opportunity to objectively quantify the deviation of high-dimensional morphometric patterns in neurons and the microvasculature from their age-related norm in a single measurement. Despite these innovative findings, further work is needed to disentangle specific physiological and pathological patterns from raw retinal age gaps to obtain sensitive, specific and clinically useful biomarkers of PD.

Strengths and limitations

The present study demonstrated several strengths including a large sample, standardised ascertainment of incident PD, standardised protocol for capturing fundus images and comprehensive adjustment of confounding factors. However, this study also had several limitations. First of all, the UK Biobank study included healthier and younger participants than the general population they were derived from due to the health selection bias [51], which may bias the association. Nevertheless, we have performed several sensitivity analyses to verify the robustness of our findings. Secondly, the limited number of incident PD cases prevented us from performing further subgroup analyses. Thirdly, due to the lack of follow-up data on fundus images, we could not investigate the association between dynamic changes of retinal age gap and incident PD. Further studies are warranted to examine the association of longitudinal retinal age gap changes and the risk of incident PD. Lastly, the possibility of residuals confounders could not be excluded.

Conclusion

In conclusion, we found that retinal age gap was associated with the future risk of incident PD. The retinal age gap can be considered a biological ageing marker that may be applied for the identification of preclinical PD patients. Further studies are necessary to investigate the association between the dynamic changes of retinal age gaps over time and the risks of PD to further validate our findings.

Declaration of Conflicts of Interest: None.

Declaration of Sources of Funding: The present work was supported by Fundamental Research Funds of the State Key Laboratory of Ophthalmology, National Natural Science Foundation of China (82000901, 82101173, 81870663, 82171075), NHMRC Investigator Grants (2010072) Outstanding Young Talent Trainee Program of Guangdong Provincial People’s Hospital (KJ12019087), Guangdong Provincial People’s Hospital Scientific Research Funds for Leading Medical Talents and Distinguished Young Scholars in Guangdong Province (KJ12019457), Talent Introduction Fund of Guangdong Provincial People’s Hospital (Y012018145), Science and Technology Program of Guangzhou, China (202002020049), Project of Special Research on Cardiovascular Diseases (2020XXG007) and Research Foundation of Medical Science and Technology of Guangdong Province (B2021237). Prof. Mingguang He receives support from the University of Melbourne at Research Accelerator Program and the CERA Foundation. The Centre for Eye Research Australia receives Operational Infrastructure Support from the Victorian State Government. The sponsor or funding organisation had no role in the design or conduct of this research.

References

1. Kalia LV, Lang AE. Parkinson’s disease. Lancet 2015; 386: 896–912.
2. Collaborators GBDPsD. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 2018; 17: 939–53.
3. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2014; 29: 1583–90.
4. Reeve A, Simcox E, Turnbull D. Ageing and Parkinson’s disease: why is advancing age the biggest risk factor? Ageing Res Rev 2014; 14: 19–30.
5. Levy G. The relationship of Parkinson disease with aging. Arch Neurol 2007; 64: 1242–6.
6. Hamczyk MR, Nevado RM, Barettino A, Fuster V, Andres V. Biological versus chronological aging: JACC focus seminar. J Am Coll Cardiol 2020; 75: 919–30.
7. Vaiserman A, Krasnienkov D. Telomere length as a marker of biological age: state-of-the-art, open issues, and future perspectives. Front Genet 2020; 11: 630186.
8. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol 2013; 14: R115.
9. Cole JH, Ritchie SJ, Bastin ME et al. Brain age predicts mortality. Mol Psychiatry 2018; 23: 1385–92.
10. Wang J, Knol MJ, Tiulpin A et al. Gray matter age prediction as a biomarker for risk of dementia. Proc Natl Acad Sci U S A 2019; 116: 21213–8.
11. Carvey PM, Punati A, Newman MB. Progressive dopamine neuron loss in Parkinson’s disease: the multiple hit hypothesis. Cell Transplant 2006; 15: 239–50.
12. Marttila RJ, Eskola J, Soppi E, Rinne UK. Immune functions in Parkinson's disease lymphocyte subsets, concanavalin A-induced suppressor cell activity and in vitro immunoglobulin production. J Neurol Sci 1985; 69: 121–31.

13. Wang H, Chen H, Gao X et al. Telomere length and risk of Parkinson's disease. Mov Disord 2008; 23: 302–5.

14. Schurks M, Buring J, Dushkes R, Gazzano JM, Zee RY, Kurth T. Telomere length and Parkinson's disease in men: a nested case-control study. Eur J Neurol 2014; 21: 93–9.

15. Chen R, Zhan Y. Association between telomere length and Parkinson's disease: a Mendelian randomization study. Neurobiol Aging 2021; 97: 144 e9–e11.

16. Forero DA, Gonzalez-Giraldo Y, Lopez-Quintero C, Castro-Vega LJ, Barreto GE, Perry G. Telomere length in Parkinson's disease: a meta-analysis. Exp Gerontol 2016; 75: 53–5.

17. Hudson G, Faini D, Stutt A et al. No evidence of substantia nigra telomere shortening in Parkinson's disease. Neurobiol Aging 2011; 32: 2107 e3–5.

18. Horvath S, Ritz BR. Increased epigenetic age and granulocyte counts in the blood of Parkinson's disease patients. Aging (Albany NY) 2015; 7: 1130–42.

19. Eickhoff CR, Hoffstaedter F, Caspers J et al. Advanced brain ageing in Parkinson's disease is related to disease duration and individual impairment. Brain Commun 2021; 3: fcb191.

20. Beheshti I, Mishra S, Sone D, Khanna P, Matsuda H. T1-weighted MRI-driven brain age estimation in Alzheimer's disease and Parkinson's disease. Aging Dis 2020; 11: 618–28.

21. Zhu Z, Shi D, Guankai P, et al. Retinal age as a predictive biomarker for mortality risk. Br J Ophthalmol 2022.

22. London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol 2013; 9: 44–53.

23. Patton N, Aslam T, Macgillivray T, Partie A, Deary IJ, Dhillon B. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvascularities. J Anat 2005; 206: 319–48.

24. Ortuno-Lizaran I, Sanchez-Saez X, Lax P et al. Dopaminergic retinal cell loss and visual dysfunction in Parkinson disease. Ann Neurol 2020; 88: 893–906.

25. Murueta-Goyena A, Barrenechea M, Erramuzpe A et al. Foveal remodeling of retinal microvasculature in Parkinson's disease. Front Neurosci 2021; 15: 708700.

26. Kromer R, Buhmann C, Hidding U et al. Evaluation of retinal vessel morphology in patients with Parkinson's disease using optical coherence tomography. PLoS One 2016; 11: e0161136.

27. Armstrong RA. Oculo-visual dysfunction in Parkinson's disease. J Parkinsons Dis 2015; 5: 715–26.

28. Sudlow C, Gallacher J, Allen N et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015; 12: e1001779.

29. Chua SYL, Thomas D, Allen N et al. Cohort profile: design and methods in the eye and vision consortium of UK biobank. BMJ Open 2019; 9: e025077.

30. Qiu C, Hu G, Kivipelto M et al. Association of blood pressure and hypertension with the risk of Parkinson disease: the national FINRISK study. Hypertension 2011; 57: 1094–100.

31. Xu Q, Park Y, Huang X et al. Diabetes and risk of Parkinson's disease. Diabetes Care 2011; 34: 910–5.

32. Kizza J, Lewington S, Mappin-Kasirer B et al. Cardiovascular risk factors and Parkinson's disease in 500,000 Chinese adults. Ann Clin Transl Neurol 2019; 6: 624–32.

33. Egberg A, Hansen PR, Gislason GH, Thyssen J. Exploring the association between rosacea and Parkinson disease: a Danish Nationwide Cohort Study. JAMA Neurol 2016; 73: 529–34.

34. Hall TO, Wan JY, Mata IF et al. Risk prediction for complex diseases: application to Parkinson disease. Genet Med 2013; 15: 361–7.

35. Cole JH, Franke K. Predicting age using neuroimaging: innovative brain ageing biomarkers. Trends Neurosci 2017; 40: 681–90.

36. Peters MJ, Jochanes R, Pilling LC et al. The transcriptional landscape of age in human peripheral blood. Nat Commun 2015; 6: 8570.

37. Samuel MA, Zhang Y, Meister M, Sanes JR. Age-related alterations in neurons of the mouse retina. J Neurosci 2011; 31: 16033–44.

38. Patel NB, Lim M, Gajjar A, Evans KB, Harwerth RS. Age-associated changes in the retinal nerve fiber layer and optic nerve head. Invest Ophthalmol Vis Sci 2014; 55: 5134–43.

39. Jorge L, Canario N, Quental H, Bernardes R, Castelo-Branco M. Is the retina a mirror of the aging brain? Aging of neural retina layers and primary visual cortex across the lifespan. Front Aging Neurosci 2019; 11: 360.

40. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson's disease. Brain 2009; 132: 1128–45.

41. Yu JG, Feng YF, Xiang Y et al. Retinal nerve fiber layer thickness changes in Parkinson disease: a meta-analysis. PLoS One 2014; 9: e85718.

42. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vision Res 2004; 44: 2793–7.

43. Robbins CB, Thompson AC, Bhullar PK et al. Characterization of retinal microvascular and choroidal structural changes in Parkinson disease. JAMA Ophthalmol 2021; 139: 182–8.

44. Kwapong WR, Ye H, Peng C et al. Retinal microvascular impairment in the early stages of Parkinson's disease. Invest Ophthalmol Vis Sci 2018; 59: 4115–22.

45. Shi C, Chen Y, Kwapong WR et al. Characterization by fractal dimension analysis of the retinal capillary network in Parkinson disease. Retina 2020; 40: 1483–91.

46. Jo YH, Sung KR, Shin JW. Effects of age on Peripapillary and macular vessel density determined using optical coherence tomography angiography in healthy eyes. Invest Ophthalmol Vis Sci 2019; 60: 3492–8.

47. Wei Y, Jiang H, Shi Y et al. Age-related alterations in the retinal microvasculature, microcirculation, and microstructure. Invest Ophthalmol Vis Sci 2017; 58: 3804–17.
48. Xu X, Wang B, Ren C et al. Recent progress in vascular aging: mechanisms and its role in age-related diseases. Aging Dis 2017; 8: 486–505.

49. Kumar S, Wang EH, Pokabla MJ, Noecker RJ. Teleophthalmology assessment of diabetic retinopathy fundus images: smartphone versus standard office computer workstation. Telemed J E Health 2012; 18: 158–62.

50. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J. Pattern of brain destruction in Parkinson's and Alzheimer's diseases. J Neural Transm (Vienna) 1996; 103: 455–90.

51. Fry A, Littlejohns TJ, Sudlow C et al. Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population. Am J Epidemiol 2017; 186: 1026–34.

Received 5 July 2021; editorial decision 14 January 2022